Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03587740
Title ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor positive breast cancer

Therapies

Ado-trastuzumab emtansine

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Duarte California 91010 United States Details
The Stamford Hospital Stamford Connecticut 06904 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Massachusetts General Hospital Boston Massachusetts 02215 United States Details
Dana-Farber Cancer Institute at St. Elizabeth's Medical Center Brighton Massachusetts 02135 United States Details
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center Milford Massachusetts 01757 United States Details
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital South Weymouth Massachusetts 02190 United States Details
Mayo Clinic Rochester Minnesota 55905 United States Details
Dana-Farber/New Hampshire Oncology-Hematology Londonderry New Hampshire 03053 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
University of North Carolina Chapel Hill North Carolina 27599 United States Details
Rex Cancer Center Raleigh North Carolina 27607 United States Details
Lifespan Cancer Institute Providence Rhode Island 02903 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field